Abstract: The present invention relates to the localized delivery of nucleic acids to cells using polyelectrolyte assemblies in the form of particles that are prepared by layer-by-layer deposition of nucleic acid and specific polycation. It also relates to compositions comprising said particles and methods for the treatment of disorders or diseases by administration of such particles.

Abstract: The present invention relates to the localized delivery of nucleic acids to cells using polyelectrolyte assemblies in the form of particles that are prepared by layer-by-layer deposition of nucleic acid and specific polycation. It also relates to compositions comprising said particles and methods for the treatment of disorders or diseases by administration of such particles.

Abstract: The present invention relates to the localized delivery of nucleic acids to cells using polyelectrolyte assemblies in the form of particles that are prepared by layer-by-layer deposition of nucleic acid and specific polycation. It also relates to compositions comprising said particles and methods for the treatment of disorders or diseases by administration of such particles.

Abstract: The present invention relates to methods and kits for predicting the risk of relapse in patients suffering from idiopathic nephrotic syndrome. No test exists for mechanistically classifying idiopathic and secondary nor for predicting the risk of relapse, with consequent non-specific and toxic treatment regimes. In particular, the present invention relates to a method of predicting the risk of relapse in a patient suffering from idiopathic nephrotic syndrome i) comprising quantifying the level of FoxP3 positive cells and the level of CMIP positive cells in a blood sample obtained from the patient, ii) comparing the level quantified at step i) with their respective predetermined reference values and iii) concluding that the patient is at risk of relapse when the level of FoxP3 positive cells is lower than its predetermined reference value and the level of CMIP positive cells is higher than its predetermined reference value.

Abstract: Provided are methods and compositions for the diagnosis of the Minimal Change Nephrotic Syndrome (MCNS) in a human by detecting and/or quantifying a biochemical marker which is specific of the disease.